ZYME - Zymeworks Inc.

NYSE - NYSE Delayed Price. Currency in USD
20.50
-0.12 (-0.58%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close20.62
Open20.52
Bid20.47 x 900
Ask20.57 x 900
Day's Range20.28 - 20.96
52 Week Range10.72 - 21.35
Volume86,640
Avg. Volume148,198
Market Cap641.435M
Beta (3Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Zymeworks to Present at Raymond James Life Sciences and MedTech Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY.

  • Business Wire13 days ago

    Zymeworks Adds Accomplished Biopharmaceutical Executives to its Board of Directors

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of two new independent members to its Board of Directors, further enhancing the Board’s commercial expertise. The new board members are Sue Mahony, Ph.D., MBA, a pharmaceutical executive with over 30 years of combined experience with Eli Lilly and Company (Lilly), Schering-Plough, Amgen, and Bristol-Myers Squibb, and Troy Cox, MBA, who has served in numerous senior leadership positions at leading biopharmaceutical companies such as Foundation Medicine, Roche-Genentech, UCB BioPharma, Sanofi-Aventis, and Schering-Plough.

  • Benzinga18 days ago

    The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...

  • Business Wire19 days ago

    Zymeworks' Lead Asset, ZW25, Granted Fast Track Designation from the FDA

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW25, a novel Azymetric™ bispecific antibody, for the first-line treatment of patients with HER2-overexpressing gastroesophageal adenocarcinoma in combination with standard of care chemotherapy. “Receipt of Fast Track designation from the FDA emphasizes the large unmet need of patients with these types of HER2-expressing cancers,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO.

  • Business Wire19 days ago

    Zymeworks Earns Milestone Payment in Merck Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has earned a milestone payment from Merck (known as MSD outside the US and Canada) achieved under the companies’ 2014 research and license agreement. Zymeworks will receive US$2.0 million in connection with Merck’s completion of a late-stage preclinical study for a bispecific antibody candidate using Zymeworks’ proprietary Azymetric™ and EFECT™ therapeutic platforms. “Merck’s completion of this milestone is great news,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks.

  • Business Wire20 days ago

    Zymeworks to Present at Jefferies 2019 Global Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Jefferies 2019 Global Healthcare Conference taking place June 4-7, 2019 in New York, NY.

  • Business Wire25 days ago

    Zymeworks Announces Corporate Update Conference Call

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships.

  • Business Wirelast month

    Zymeworks and GSK Expand 2016 Azymetric™ Bispecific Agreement

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas.

  • Business Wirelast month

    Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer. “We believe this first ZymeLink licensing deal provides further validation of our novel ADC technology, which is already being used in Zymeworks’ own clinical candidate, ZW49,” said Ali Tehrani, Ph.D., President and Chief Executive Officer of Zymeworks. “Historically, traditional ADC development has been plagued by a number of challenges related to toxicity and efficacy.

  • Business Wirelast month

    Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 2, 2019 .

  • Business Wire2 months ago

    Zymeworks Reports 2019 First Quarter Financial Results

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March 31, 2019.

  • Business Wire2 months ago

    Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced it has expanded its leadership team with the hiring of three new vice presidents to support the Company’s expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and ...

  • Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
    Business Wire2 months ago

    Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform

    VANCOUVER, British Columbia VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.-- -- One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements Zymeworks to receive US$3.5 million commercial license payment from Daiichi Sankyo Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ...

  • Business Wire2 months ago

    Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co.

  • Business Wire2 months ago

    Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas. “Advancing ZW25 into a Phase 2 clinical trial represents another key milestone for Zymeworks,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “This reaffirms our commitment to execute our ambitious drug development strategy to address unmet need in patients with HER2-expressing cancers across multiple indications and lines of therapy.

  • GlobeNewswire3 months ago

    Positive Results and New Technology Give Rise to Antibody Dominance

    POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 -- Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot.

  • Business Wire3 months ago

    Zymeworks Reports 2018 Year-End Financial Results

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2018.

  • Business Wire3 months ago

    Zymeworks to Present at Barclays 2019 Global Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...

  • Business Wire5 months ago

    Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

    VANCOUVER, British Columbia-- -- Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials Zymeworks to receive milestone payment of US$8.0 million for this second IND submission Lilly is one of eight pharma partners; INDs by others anticipated Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion Zymeworks ...

  • Business Wire5 months ago

    Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.

  • Business Wire6 months ago

    Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

    VANCOUVER, Canada-- -- ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates Complete tumor regressions observed in high and low HER2-expressing models Superior preclinical efficacy compared to approved HER2 ADCs Toxicology results support clinical dosing well above predicted efficacy levels Potential to address unmet need in high and low ...

  • Reuters7 months ago

    BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates

    Nov 27 (Reuters) - Beigene Ltd: * ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND ...

  • Business Wire7 months ago

    Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

    BeiGene acquires exclusive development and commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan), Australia, and New Zealand. The companies will collaborate on joint global development for selected indications. BeiGene also acquires licenses for Zymeworks’ Azymetric™ and EFECT™ platforms to develop and commercialize up to three bispecific antibody therapeutics globally directed to BeiGene's targets.

  • Business Wire7 months ago

    Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

    DUBLIN-- -- ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary ...